Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDA pulls approval for avastin in breast cancer.

Literature DB >> 22586694

FDA pulls approval for avastin in breast cancer.

Abstract

The FDA has revoked approval of the breast cancer indication for bevacizumab (Avastin; Genetech), saying that studies have not shown enough of a benefit to outweigh the drug's serious and potentially life-threatening side effects.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2011 PMID： 22586694 DOI： 10.1158/2159-8290.CD-ND112311OL-08

Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397

Keyword Cloud
Cited

10 in total

1. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.

Authors: Clemens C Cyran; Yanjun Fu; Victor Rogut; Bundit Chaopathomkul; Michael F Wendland; David M Shames; Robert C Brasch
Journal: Acad Radiol Date: 2013-10 Impact factor: 3.173

Review 2. On glioblastoma and the search for a cure: where do we stand?

Authors: John Bianco; Chiara Bastiancich; Aleksander Jankovski; Anne des Rieux; Véronique Préat; Fabienne Danhier
Journal: Cell Mol Life Sci Date: 2017-02-17 Impact factor: 9.261

3. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.

Authors: M Di Salvatore; L Lo Giudice; E Rossi; C Santonocito; G Nazzicone; M G Rodriquenz; S Cappuccio; A Inno; P Fuso; A Orlandi; A Strippoli; E Capoluongo; A Astone; A Cassano; C Barone
Journal: Clin Transl Oncol Date: 2015-07-04 Impact factor: 3.405

Review 10. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.

Authors: Xuelei Ma; Xiaoshan Wang; Jingwen Huang; Yingtai Chen; Jing Zhang; Binglan Zhang; Changle Shi; Lei Liu
Journal: PLoS One Date: 2016-08-31 Impact factor: 3.240

10 in total

FDA pulls approval for avastin in breast cancer.

1. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.

Review 2. On glioblastoma and the search for a cure: where do we stand?

3. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.

4. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?

Review 5. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.

Review 6. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.

7. A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer.

8. Update on triple-negative breast cancer: prognosis and management strategies.

9. Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.

Review 10. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.